{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-25-001949","form_type":"8-K","ticker":"VXRT","cik":"0000072444","company_name":"Vaxart, Inc.","filed_at":"2025-01-28T23:59:59+00:00","discovered_at":"2026-05-14T18:03:06.200319+00:00","generated_at":"2026-05-27T08:43:30.563896+00:00","sec_items":["5.02","7.01","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Vaxart appoints Kevin Finney to board; Robert Yedid resigns","bullets":["Kevin Finney appointed to Vaxart board effective Jan 28, 2025; will serve on Audit and Nominating/Governance committees.","Robert A. Yedid resigned from board on Jan 28, 2025 for personal reasons; no disagreement with the company.","Elaine J. Heron appointed to Compensation Committee effective Jan 28, 2025.","Finney is CEO/President of Autobahn Therapeutics and brings 35 years of biotech leadership experience."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-25-001949","json":"https://secwatch.observer/filing/0001437749-25-001949.json","markdown":"https://secwatch.observer/filing/0001437749-25-001949.md","text":"https://secwatch.observer/filing/0001437749-25-001949.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/72444/000143774925001949/0001437749-25-001949-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/72444/000143774925001949/vxrt20250127_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-27T08:43:30.563896+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"4b9eebbc61","claim":"Robert A. Yedid resigned as Director at Vaxart, Inc..","evidence_excerpt":"Robert A. Yedid resigned from the Board and any committees of the Board, effective January 28, 2025","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/72444/000143774925001949/0001437749-25-001949-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"cdc8d0d747","claim":"Kevin Finney was appointed as Director at Vaxart, Inc..","evidence_excerpt":"the Board appointed Kevin Finney to serve on the Board, effective January 28, 2025","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/72444/000143774925001949/0001437749-25-001949-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}